98%
921
2 minutes
20
The first three enzymatic steps of the strigolactone biosynthetic pathway catalysed by β-carotene cis-trans isomerase Dwarf27 (D27) from Oryza sativa and carotenoid cleavage dioxygenases CCD7 and CCD8 from Arabidopsis thaliana have been reconstituted in vitro, and kinetic assays have been developed for each enzyme, in order to develop selective enzyme inhibitors. Recombinant OsD27 shows a UV-visible λmax at 422 nm and is inactivated by silver(I) acetate, consistent with the presence of an iron-sulfur cluster that is used in catalysis. OsD27 and AtCCD7 are not inhibited by hydroxamic acids that cause shoot branching in planta, but OsD27 is partially inhibited by terpene-like hydroxamic acids. The reaction catalysed by AtCCD8 is shown to be a two-step kinetic mechanism using pre-steady-state kinetic analysis. Kinetic evidence is presented for acid-base catalysis in the CCD8 catalytic cycle and the existence of an essential cysteine residue in the CCD8 active site. AtCCD8 is inhibited in a time-dependent fashion by hydroxamic acids D2, D4, D5 and D6 (> 95% inhibition at 100 μm) that cause a shoot branching phenotype in A. thaliana, and selective inhibition of CCD8 is observed using hydroxamic acids D13H and D15 (82%, 71% inhibition at 10 μm). The enzyme inhibition data imply that the biochemical basis of the shoot branching phenotype is due to inhibition of CCD8.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/febs.13400 | DOI Listing |
Int J Biol Macromol
September 2025
CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu, Jammu & Kashmir 180001, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India. Electronic address:
Cross-linked enzyme aggregates (CLEAs) offer a promising strategy for enzyme immobilization, enhancing reusability, high enzyme loading capacity, carrier-free nature, enhanced thermal or operational stability, and ease of preparation and suitability for industrial-scale applications. This study presents the development and optimization of CLEAs of crude amidase from Bacillus smithii IIIMB2907 for efficient biocatalytic synthesis of pharmaceutically important hydroxamic acids from amides. By optimizing key preparation parameters, a robust immobilized biocatalyst was established that retains high activity and stability during repeated use.
View Article and Find Full Text PDFActa Crystallogr F Struct Biol Commun
September 2025
Lund Protein Production Platform and Protein Production Sweden, Department of Biology, Lund University, Sölvegatan 35, 22362 Lund, Sweden.
Histone deacetylase inhibitors (HDACi) are widely used in cancer therapy but often suffer from off-target effects due to their pan-inhibitory activity towards zinc-dependent enzymes. Vorinostat (SAHA), a hydroxamate-based HDACi, has been shown to lack isoform selectivity, potentially leading to unintended interactions with other metalloenzymes. Here, we report high-resolution crystal structures of SAHA bound to human carbonic anhydrase II (CA II) and a carbonic anhydrase IX (CA IX) active-site mimic.
View Article and Find Full Text PDFComput Biol Med
August 2025
Laboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, United States; Cheminformatics Laboratory, Department of Chemistry, Center for Exact and Natural Sciences (CCEN), Federal Un
The treatment of hematological cancers with hybrid kinase and histone deacetylase (HDAC) inhibitors represents a novel strategy to overcome acquired drug resistance. We curated half-maximal inhibitory concentration (IC) datasets from the ChEMBL database, including 13 cancer cell lines (72 h cytotoxicity by MTT), inhibitors of 38 kinases, and 10 HDAC isoforms identified through target fishing and literature review. Rigorous biological and chemical curation produced datasets ranging from 76 to 8173 compounds, depending on the target.
View Article and Find Full Text PDFInt J Mol Sci
August 2025
Department of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan.
Domatinostat is an inhibitor of class I histone deacetylases, whose safety and efficacy as a cancer therapeutic has been demonstrated in a recent phase II study in patients with esophagogastric adenocarcinoma. We previously showed that domatinostat exhibited preferential cytotoxic activity against glioma stem cells (GSCs) compared to their differentiated counterparts. However, the underlying mechanism behind the preferential cytotoxicity is yet to be elucidated.
View Article and Find Full Text PDFPathol Res Pract
October 2025
Department of Hepatobiliary and Pancreatic Surgery, Second Affiliated Hospital of Kunming Medical University, China. Electronic address:
Objective: Pancreatic cancer is one of the most aggressive malignant tumors in humans, with poor prognosis. The acetylase tumor inhibitor (Pracinostat) has been shown to suppress the growth of various tumors. This study aimed to investigate the effects of Pracinostat on the pancreatic cancer cell line BxPC3 and to explore the underlying molecular mechanisms through both in vivo and in vitro experiments.
View Article and Find Full Text PDF